Why Barclays is raising its 2025 S&P target
Venu Krishna, Barclays head of U.S. equity strategy, joins CNBC’s ‘Money Movers’ to discuss his outlook on the markets heading into 2025, potential headwinds for the markets next year, and more.
Similar Posts
Coterra Energy is far superior to Devon Energy
Byadmin
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Mad Money with Jim Cramer ‘Mad Money’ host Jim Cramer weighs in on stock including: Transmedics, Amphenol, and Devon Energy. 03:21 8 minutes ago Jim Cramer Source link
Jim Cramer takes a closer look at the state of the Trump trade
Byadmin
‘Mad Money’ host Jim Cramer looks at the state of the Trump trade. Source link
‘Biggest disappointment’ for the West is China isn’t aligning with it: Ian Bremmer
Byadmin
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Ian Bremmer, founder of Eurasia Group, says China is getting more powerful and not aligning with the West. This will lead to separate systems like two separate Internets. 01:57 Wed, Oct 10 201811:49 PM EDT Source link
Fed's Powell: It will take time for the labor market to stabilize
Byadmin
Federal Reserve Chair Jerome Powell speaks to business leaders in the Dallas-Fort Worth area on monetary policy. Powell delivered a speech followed by a Q&A session. Source link
ResMed expands Singapore ops to address obstructive sleep conditions
Byadmin
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Mick Farrell, CEO of medical equipment maker ResMed, says the company is pouring “tens of millions of dollars” into expanding its Singapore operations as it aims to help 500 million people sleep better with its devices. Source link
Mizuho’s Jared Holz on what Trump’s FDA pick means for biotech innovation
Byadmin
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Fast Money Mizuho’s Jared Holz joins ‘Fast Money’ to talk what’s next for biopharma space after president-elect Trump names his pick for FDA head. 05:40 28 minutes ago Source link